Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Margaret Macro"'
Autor:
Romain Lannes, Mehmet Samur, Aurore Perrot, Celine Mazzotti, Marion Divoux, Titouan Cazaubiel, Xavier Leleu, Anaïs Schavgoulidze, Marie-Lorraine Chretien, Salomon Manier, Didier Adiko, Frederique Orsini-Piocelle, François Lifermann, Sabine Brechignac, Lauris Gastaud, Didier Bouscary, Margaret Macro, Alice Cleynen, Mohamad Mohty, Nikhil Munshi, Jill Corre, Hervé Avet-Loiseau
Publikováno v:
Journal of Clinical Oncology. 41:1695-1702
PURPOSE Multiple myeloma (MM) is characterized by copy number abnormalities (CNAs), some of which influence patient outcomes and are sometimes observed only at relapse(s), suggesting their acquisition during tumor evolution. However, the presence of
Autor:
Elena Zamagni, Cristina Nanni, Luca Dozza, Thomas Carlier, Clément Bailly, Paola Tacchetti, Annibale Versari, Stephane Chauvie, Andrea Gallamini, Barbara Gamberi, Denis Caillot, Francesca Patriarca, Margaret Macro, Mario Boccadoro, Laurent Garderet, Simona Barbato, Stefano Fanti, Aurore Perrot, Francesca Gay, Peter Sonneveld, Lionel Karlin, Michele Cavo, Caroline Bodet-Milin, Philippe Moreau, Françoise Kraeber-Bodéré
Publikováno v:
Journal of Clinical Oncology
Journal of Clinical Oncology, 2020, 38, Online ahead of print. ⟨10.1200/JCO.20.00386⟩
Journal of Clinical Oncology, American Society of Clinical Oncology, 2020, 38, Online ahead of print. ⟨10.1200/JCO.20.00386⟩
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(2), 116-125
Journal of Clinical Oncology, 2020, 38, Online ahead of print. ⟨10.1200/JCO.20.00386⟩
Journal of Clinical Oncology, American Society of Clinical Oncology, 2020, 38, Online ahead of print. ⟨10.1200/JCO.20.00386⟩
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(2), 116-125
PURPOSE 18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) is currently the standard technique to define minimal residual disease (MRD) status outside the bone marrow (BM) in patients with multiple myeloma (MM).
Autor:
Thierry Facon, Shaji Kumar, Torben Plesner, Philippe Moreau, Nizar J. Bahlis, Hartmut Goldschmidt, Michael O'Dwyer, Aurore Perrot, Christopher P. Venner, Katja Weisel, Joseph R. Mace, Noopur S. Raje, Mourad Tiab, Margaret Macro, Laurent Frenzel, Xavier Leleu, Huiling Pei, Fredrik Borgsten, Saad Zafar Usmani
Publikováno v:
Journal of Clinical Oncology. 40:8044-8044
8044 Background: In the phase 3 MAIA study, adding DARA to Rd improved progression-free survival (primary endpoint), overall survival, duration of response, and PROs in transplant-ineligible pts with NDMM. We report a MAIA subgroup analysis of time t
Autor:
Cyrille Touzeau, Aurore Perrot, Cyrille Hulin, Salomon Manier, Margaret Macro, Denis Caillot, Lionel Karlin, Olivier Decaux, Caroline Jacquet, Mourad Tiab, Xavier Leleu, Lucie Planche, Herve Avet-Loiseau, Philippe Moreau
Publikováno v:
Journal of Clinical Oncology. 40:8002-8002
8002 Background: High-risk (HR) cytogenetic is associated with poor outcome in transplant eligible (TE) newly diagnosed myeloma multiple myeloma (NDMM). The triplet combination carfilzomib lenalidomide and dexamethasone (KRD) plus transplantation dem
Autor:
Xavier Leleu, Margaret Macro, Cyrille Touzeau, Clara Mariette, Salomon Manier, Sabine Brechignac, Laure Vincent, Benjamin Hebraud, Olivier Decaux, Samantha Schulmann, Caroline Lenoir, Pascal Godmer, Agathe Farge, Laure Peyro Saint Paul, Jean-Jacques Parienti
Publikováno v:
Journal of Clinical Oncology. 40:8000-8000
8000 Background: Frail patients with multiple myeloma have an inferior outcome, especially in the relapse setting. This adverse prognosis is mainly related to a high discontinuation rate due to treatment (Tx) related adverse events. The aim of this p
Autor:
Paul G. Richardson, Hervé Avet-Loiseau, Benoit Dupas, Martine Escoffre-Barbe, Aurore Perrot, Eric Frampas, Caroline Bodet-Milin, Lotfi Benboubker, Michel Attal, Thierry Facon, Gerald Marit, Jean-Richard Eveillard, Florence Caillon, Cyrille Hulin, Véronique Dorvaux, Lionel Karlin, Carine Chaleteix, Denis Caillot, Anne-Marie Stoppa, Brigitte Pegourie, Philippe Moreau, Kamel Laribi, Laurent Garderet, Jean-Michel Nguyen, Nikhil C. Munshi, Kenneth C. Anderson, Aurélie Gaultier, Margaret Macro, Françoise Kraeber-Bodéré
Publikováno v:
Journal of Clinical Oncology. 35:2911-2918
Purpose Magnetic resonance imaging (MRI) and positron emission tomography–computed tomography (PET-CT) are important imaging techniques in multiple myeloma (MM). We conducted a prospective trial in patients with MM aimed at comparing MRI and PET-CT
Autor:
Sonja Zweegman, Xavier Leleu, Christopher Chiu, Marie-Christine Béné, Pieter Sonneveld, Tahamtan Ahmadi, Michel Delforge, Michel Attal, Cyrille Hulin, Thierry Facon, Jessica Vermeulen, Aurore Perrot, Denis Caillot, Margaret Macro, Lixia Pei, Hervé Avet-Loiseau, Thomas Dejoie, Philippe Moreau, Jérôme Lambert, Annemiek Broijl
Publikováno v:
Journal of Clinical Oncology. 37:8003-8003
8003 Background: VTd is a standard of care (SoC) for TE NDMM. CD38 mAb DARA significantly reduced the risk of progression/death and improved CR and MRD-negative rates in relapsed refractory MM or transplant-ineligible NDMM in phase 3 studies. We repo
Autor:
Hareth Nahi, Noopur Raje, Torben Plesner, Maria Krevvata, Aurore Perrot, Rachel Kobos, Philippe Moreau, Margaret Macro, Michel Attal, Thierry Facon, Cyrille Hulin, Katja Weisel, Hang Quach, Xavier Leleu, Jianping Wang, Chris Venner, Supratik Basu, Saad Z. Usmani, Shaji Kumar
Publikováno v:
Web of Science
8035 Background: D-Rd significantly reduced the risk of progression/death by 44% in transplant-ineligible NDMM pts vs Rd in the phase 3 MAIA study. To examine the impact of age on efficacy/safety of D-Rd vs Rd in this population, a subgroup analysis
Autor:
Aurore Perrot, Laurent Garderet, Pieter Sonneveld, Margaret Macro, Bertrand Arnulf, Jérôme Lambert, Soraya Wuilleme, Michel Attal, Cyrille Hulin, Jill Corre, Lionel Karlin, Christopher Chiu, Lixia Pei, Tobias Kampfenkel, Mark-David Levin, Hervé Avet-Loiseau, Marie-Christine Béné, Saskia K. Klein, Philippe Moreau, Carla de Boer
Publikováno v:
Journal of Clinical Oncology. 37:8017-8017
8017 Background: In TE NDMM patients (pts), the CD38 monoclonal antibody DARA significantly reduced the risk of progression/death and improved stringent CR, ≥CR, and MRD-negative rates when added to VTd in the phase 3 CASSIOPEIA study. MRD status a
Autor:
Loïc Campion, Stephane Minvielle, Jean-Luc Harousseau, Lotfi Benboubker, Philippe Moreau, Marc Wetterwald, Anne-Marie Stoppa, Catherine Guérin-Charbonnel, Denis Caillot, Gerald Marit, Brigitte Kolb, Xavier Leleu, Claire Mathiot, Laurent Voillat, Thierry Facon, Michel Attal, Cyrille Hulin, Hervé Avet-Loiseau, Murielle Roussel, Margaret Macro
Publikováno v:
Journal of Clinical Oncology. 28:4630-4634
Purpose Cytogenetics is an important prognostic parameter in multiple myeloma (MM). Patients presenting with either t(4;14) or del(17p) are known to have a short event-free survival (EFS) and overall survival (OS). Some preliminary data suggest that